Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial

Ommen-Nijhof, A. van; Konings, I.R.; Zeijl, C.J.J. van; Uyl-de Groot, C.A.; Noort, V. van der; Jager, A.; ... ; SONIA Study Steering Comm (2018)

Article / Letter to editor

• Advanced breast cancer
• Metastatic breast cancer
• Palbociclib
• Ribociclib
• Abemaciclib
• CDK4
• 6 inhibitors
• Non-steroidal aromatase inhibitors
• Fulvestrant

• All authors: Ommen-Nijhof, A. van; Konings, I.R.; Zeijl, C.J.J. van; Uyl-de Groot, C.A.; Noort, V. van der; Jager, A.; Sonke, G.S.; SONIA Study Steering Comm
• Date: 2018-11-20
• Journal: BMC Cancer
• Volume: 18
• DOI: doi:10.1186/s12885-018-4978-1